Lonza Group AG Overview
Pro stress-test →Lonza Group AG is the world's largest contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotech industries. The company operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. It derives its revenue primarily from long-term supply agreements with pharmaceutical customers and provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply.
Strategic Profile
Pro stress-test →Lonza reported strong Q1 2026 performance and confirmed its full-year guidance, reinforcing its position as a leading CDMO in the global healthcare sector. The company's focus on biologics, advanced synthesis, and specialized modalities positions it to benefit from long-term trends in drug development and outsourcing. Lonza confirmed expectations for 11–12% constant-exchange-rate (CER) sales growth for 2026.
Competitive Landscape
Pro stress-test →Competitors include Siegfried Holding, CordenPharma, Patheon, DPT Laboratories, and KBI BioPharma among others in the CDMO market. Lonza maintains competitive advantage through its scale as the world's largest CDMO, diversified business platform across multiple modalities, and global manufacturing footprint.
Industry Context
Lonza Group AG operates in Contract Development and Manufacturing Organizations (CDMO).
Key facts
Headquarters: Basel, Switzerland · Revenue: $7.86B · Market cap: $44.5B